MADRIGAL PHARMACEUTICALS, INC. (MDGL) FY2025 10-K Annual Report
MADRIGAL PHARMACEUTICALS, INC. (MDGL) 10-K annual report for fiscal year 2025, filed with SEC EDGAR on Feb 19, 2026. This page provides AI-powered analysis including business overview, management discussion & analysis (MD&A), risk factors, and key financial data such as revenue, net income, gross margin, operating margin, and return on equity (ROE) extracted from XBRL.
MADRIGAL PHARMACEUTICALS, INC. FY2025 10-K Analysis
Business Overview
- • Core business model: development and commercialization of pharmaceutical therapies for liver diseases, primarily noncirrhotic MASH
- • New product: Launch and full-year commercialization of Rezdiffra in U.S. (approved Mar 2024) and market entry in Germany (Sep 2025)
Management Discussion & Analysis
- • No revenue or YoY change figures provided in the MD&A
- • No profitability or margin percentages disclosed
Risk Factors
- • Regulatory risk: accelerated approval of Rezdiffra under FDA Subpart H pathway contingent on completing MAESTRO-NASH trials for full approval
- • Geopolitical/macro risk: U.S. Medicare drug price negotiation program starting 2026 may cap prices and impose rebates on high-spend drugs like Rezdiffra
MADRIGAL PHARMACEUTICALS, INC. FY2025 Key Financial MetricsXBRL
Revenue
$958M
▲ +432.1% YoY
Net Income
-$288M
▲ +38.1% YoY
Operating Margin
-31.3%
▲ +24508bp YoY
Net Margin
-30.1%
▲ +22856bp YoY
ROE
-47.8%
▲ +1393bp YoY
Total Assets
$1.3B
▲ +20.9% YoY
EPS (Diluted)
$-12.85
▲ +41.3% YoY
Operating Cash Flow
-$190M
▲ +58.4% YoY
Source: XBRL data from MADRIGAL PHARMACEUTICALS, INC. FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on MADRIGAL PHARMACEUTICALS, INC.
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.